DUBLIN – Minoryx Therapeutics SL raised €21.3 million (US$25 million) in a series B round to move its lead drug candidate, MIN-102, into at least two additional indications, on top of its lead indication adrenomyeloneuropathy (AMN), in which it is currently undergoing a phase II/III trial.